Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Zynerba Pharmaceuticals, Inc. (ZYNE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 EFFECT Form EFFECT - Notice of Effectiveness:
10/11/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/11/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
10/11/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
10/11/2023 8-K Quarterly results
10/11/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
10/04/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
09/29/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
09/27/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
09/27/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
08/24/2023 SC 13D Harmony Biosciences Holdings, Inc. reports a 13.1% stake in ZYNERBA PHARMACEUTICALS, INC.
08/14/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
08/14/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
08/14/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
08/14/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
08/14/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "AGREEMENT AND PLAN OF MERGER   by and among   HARMONY BIOSCIENCES HOLDINGS, INC.,   XYLOPHONE ACQUISITION CORP.   and   ZYNERBA PHARMACEUTICALS, INC.",
"AMENDMENT TO EMPLOYMENT AGREEMENT",
"AMENDMENT TO EMPLOYMENT AGREEMENT",
"AMENDMENT TO EMPLOYMENT AGREEMENT",
"Execution Version TENDER AND SUPPORT AGREEMENT",
"HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC."
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/15/2023 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights",
"FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy